Thrombocytopenic Purpura, Autoimmune (AITP)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenic Purpura, Autoimmune

MalaCards integrated aliases for Thrombocytopenic Purpura, Autoimmune:

Name: Thrombocytopenic Purpura, Autoimmune 56 74 58 13
Idiopathic Thrombocytopenic Purpura 56 12 74 52 15 39 32
Autoimmune Thrombocytopenic Purpura 12 52 15 17
Immune Thrombocytopenic Purpura 56 12 58 71
Immune Thrombocytopenia 58 36 62
Itp 56 52 58
Thrombocytopenia Due to Platelet Alloimmunization 71
Purpura, Thrombocytopenic, Idiopathic 43
Immune Thrombocytopenic Purpura; Itp 56
Thrombocytopenic Purpura Autoimmune 52
Purpura Thrombocytopenic Idiopathic 54
Primary Thrombocytopenic Purpura 12
Ideopath Thrombocytopenic Pur 12
Autoimmune Thrombocytopenia 71
Idiopathic Purpura 12
Werlhof's Disease 12
Aitp 56


Orphanet epidemiological data:

immune thrombocytopenic purpura
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: All ages;


autosomal dominant form


thrombocytopenic purpura, autoimmune:
Inheritance autosomal dominant inheritance


Orphanet: 58  
Rare haematological diseases

External Ids:

Disease Ontology 12 DOID:8924
OMIM 56 188030
KEGG 36 H01240
ICD9CM 34 287.31
MeSH 43 D016553
NCIt 49 C3446
SNOMED-CT 67 13172003 32273002
ICD10 32 D69.3
MESH via Orphanet 44 D016553
ICD10 via Orphanet 33 D69.3
UMLS via Orphanet 72 C0398650
Orphanet 58 ORPHA3002
MedGen 41 C0398650
UMLS 71 C0242584 C0272286 C0398650

Summaries for Thrombocytopenic Purpura, Autoimmune

KEGG : 36 Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder, and the most common cause of isolated thrombocytopenia in children. Destruction of autoantibody-sensitized platelets by Fc[gamma]R-bearing phagocytic cells in the reticuloendothelial system plays an important role. ITP is diagnosed clinically, based upon onset of thrombocytopenia in the absence of other hematologic abnormalities, or other causes of low platelets, and with a characteristic blood smear. While around 50% of typical childhood acute ITP is preceded by a viral or bacterial infection and commonly resolves within weeks to months without treatment, fewer adult cases are acute and self-resolving. Typical adult primary ITP is very similar clinically to chronic pediatric ITP. Intravenous immunoglobulin (IVIg) treatment and splenectomy (removal of the platelet-destructing organ) are effective treatment options. It has been reported that the activating FCGR2C-ORF genotype predisposes to ITP by altering the balance of activating and inhibitory Fc[gamma]R on immune cells.

MalaCards based summary : Thrombocytopenic Purpura, Autoimmune, also known as idiopathic thrombocytopenic purpura, is related to thrombocytopenia due to platelet alloimmunization and acquired thrombocytopenia. An important gene associated with Thrombocytopenic Purpura, Autoimmune is FCGR2C (Fc Fragment Of IgG Receptor IIc (Gene/Pseudogene)), and among its related pathways/superpathways are Phagosome and Osteoclast differentiation. The drugs Lansoprazole and Dexlansoprazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are thromboembolism and thrombocytopenia

Disease Ontology : 12 A primary thrombocytopenia that involves relatively few platelets in blood as a result of autoantibodies.

NIH Rare Diseases : 52 Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune system . Symptoms may include bruising, nosebleed or bleeding in the mouth, bleeding into the skin, and abnormally heavy menstruation . With treatment, the chance of remission (a symptom-free period) is good. Rarely, ITP may become a chronic ailment in adults and reappear, even after remission.

OMIM : 56 Autoimmune thrombocytopenic purpura is characterized by a low platelet count, normal bone marrow, and the absence of other causes of thrombocytopenia. It is principally a disorder of increased platelet destruction mediated by autoantibodies to platelet-membrane antigens (George et al., 1994). (188030)

PubMed Health : 62 About immune thrombocytopenia: Immune thrombocytopenia (THROM-bo-si-toe-PE-ne-ah), or ITP, is a bleeding disorder. In ITP, the blood doesn't clot as it should. This is due to a low number of blood cell fragments called platelets (PLATE-lets) or thrombocytes (THROM-bo-sites). Platelets are made in your bone marrow along with other kinds of blood cells. They stick together (clot) to seal small cuts or breaks on blood vessel walls and stop bleeding.

Wikipedia : 74 Immune thrombocytopenia purpura (ITP), also known as idiopathic thrombocytopenic purpura, is a type of... more...

Related Diseases for Thrombocytopenic Purpura, Autoimmune

Diseases related to Thrombocytopenic Purpura, Autoimmune via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 877)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia due to platelet alloimmunization 31.8 THPO SELP MPL ITGB3 ITGA2B ICOSLG
2 acquired thrombocytopenia 31.1 THPO MPL ITGB3 IL11
3 thrombocytosis 31.1 THPO SELP MPL IL11
4 polycythemia 31.0 THPO MPL ITGB3
5 neutropenia 30.9 THPO MPL IL11 IFNA2
7 thrombocytopenia 3 30.7 THPO MPL
8 hemoglobinuria 30.7 THPO SELP MPL
9 thrombasthenia 30.7 SELP ITGB3 ITGA2B GP1BA
10 evans' syndrome 30.6 THPO MPL LRBA CD40LG
11 thrombotic thrombocytopenic purpura 30.6 SELP ITGB3 CD40LG
12 qualitative platelet defect 30.6 ITGA2B GP1BA
13 fetal and neonatal alloimmune thrombocytopenia 30.4 ITGB3 ITGA2B GP1BA
14 splenic sequestration 30.4 THPO MPL ITGA2B CD40LG
15 polycythemia vera 30.4 THPO SELP MPL ITGB3 IFNA2
16 cryoglobulinemia, familial mixed 30.4 IFNA2 CD40LG
17 portal vein thrombosis 30.3 SELP MPL IFNA2 CD40LG
18 fournier gangrene 30.3 F8 CD40LG
19 common cold 30.2 SELP IFNA2 ICOSLG
20 thrombophlebitis 30.2 SELP F8 CD40LG
21 pulmonary embolism 30.2 GP6 F8 CD40LG
22 herpes zoster 30.1 IFNA2 ICOSLG CD40LG
23 myelofibrosis 30.1 THPO SELP MPL IFNA2 CD40LG
24 arteriosclerosis 30.1 SELP ITGB3 ITGA2B IL18
25 von willebrand's disease 30.1 SELP ITGB3 GP6 GP1BA F8
26 coronary thrombosis 30.1 SELP ITGB3 ITGA2B GP6 GP1BA
27 hemorrhagic disease 30.1 GP6 GP1BA F8 CD40LG
28 aplastic anemia 30.0 THPO MPL ITGB3 ITGA2B IL18 IL11
29 leukemia, acute myeloid 30.0 THPO MPL ITGB3 ITGA2B ICOSLG DNMT3B
30 deficiency anemia 30.0 THPO SELP RHD MPL IL11 IFNA2
31 glanzmann thrombasthenia 30.0 SELP ITGB3 ITGA2B GP1BA F8
32 dermatitis, atopic 30.0 SELP IL18 ICOSLG GATA3 CD40LG
33 thrombophilia 29.9 SELP ITGB3 F8 CD40LG
34 dengue disease 29.9 THPO IL11 ICOSLG CD40LG
35 myeloproliferative neoplasm 29.8 THPO SELP MPL ITGB3 IFNA2
36 x-linked recessive disease 29.7 ICOSLG F8 CD40LG
37 leukemia, chronic myeloid 29.7 THPO SELP MPL ITGB3 IL11 IFNA2
38 rheumatic disease 29.7 IL18 IL11 ICOSLG CD40LG
39 cerebrovascular disease 29.5 SELP ITGB3 ITGA2B GP1BA F8 CD40LG
40 thrombosis 29.5 SELP MPL ITGB3 ITGA2B GP6 GP1BA
41 gray platelet syndrome 29.5 SELP ITGA2B GP6 GP5 CD40LG
42 myocardial infarction 29.5 SELP ITGB3 ITGA2B IL18 GP6 GP1BA
43 essential thrombocythemia 29.4 THPO SELP MPL ITGB3 ITGA2B IL11
44 inflammatory bowel disease 29.3 SELP S100A8 LRBA IL18 IL11 ICOSLG
45 bernard-soulier syndrome 29.3 THPO SELP ITGB3 ITGA2B GP6 GP5
46 immune deficiency disease 29.3 IL18 ICOSLG DNMT3B CD40LG
47 vascular disease 29.2 SELP ITGB3 ITGA2B IL18 GP1BA F8
48 primary thrombocytopenia 29.0 THPO SELP RHD MPL ITGB3 ITGA2B
49 thrombocytopenia 28.6 THPO SELP RHD MPL ITGB3 ITGA2B
50 blood platelet disease 28.5 THPO SELP MPL ITGB3 ITGA2B IL11

Graphical network of the top 20 diseases related to Thrombocytopenic Purpura, Autoimmune:

Diseases related to Thrombocytopenic Purpura, Autoimmune

Symptoms & Phenotypes for Thrombocytopenic Purpura, Autoimmune

Human phenotypes related to Thrombocytopenic Purpura, Autoimmune:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 thromboembolism 58 31 hallmark (90%) Very frequent (99-80%) HP:0001907
2 thrombocytopenia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001873
3 petechiae 58 31 frequent (33%) Frequent (79-30%) HP:0000967
4 arterial thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004420
5 gingival bleeding 58 31 occasional (7.5%) Occasional (29-5%) HP:0000225
6 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
7 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
8 bruising susceptibility 58 31 occasional (7.5%) Occasional (29-5%) HP:0000978
9 cerebral hemorrhage 58 31 very rare (1%) Very rare (<4-1%) HP:0001342
10 abnormal bleeding 31 HP:0001892
11 purpura 58 Frequent (79-30%)
12 platelet antibody positive 31 HP:0003454

Symptoms via clinical synopsis from OMIM:

bleeding diathesis

platelet antibody

Clinical features from OMIM:


MGI Mouse Phenotypes related to Thrombocytopenic Purpura, Autoimmune:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CD40LG DNMT3B F8 GATA3 GP1BA GP6
2 homeostasis/metabolism MP:0005376 9.83 CD40LG DNMT3B F8 GATA3 GP1BA GP5
3 immune system MP:0005387 9.4 CD40LG DNMT3B F8 GATA3 GP6 IL18

Drugs & Therapeutics for Thrombocytopenic Purpura, Autoimmune

PubMed Health treatment related to Thrombocytopenic Purpura, Autoimmune: 62

Treatment for immune thrombocytopenia (ITP) is based on how much and how often you're bleeding and your platelet count. Adults who have mild ITP may not need any treatment , other than watching their symptoms and platelet counts. Adults who have ITP with very low platelet counts or bleeding problems often are treated. The acute (short-term) type of ITP that occurs in children often goes away within a few weeks or months. Children who have bleeding symptoms, other than merely bruising (purpura ), usually are treated. Children who have mild ITP may not need treatment other than monitoring and followup to make sure their platelet counts return to normal.

Drugs for Thrombocytopenic Purpura, Autoimmune (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Morphine Approved, Investigational Phase 4 57-27-2 5288826
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
alemtuzumab Approved, Investigational Phase 4 216503-57-0
Clarithromycin Approved Phase 4 81103-11-9 84029
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
Caffeic acid Experimental, Investigational Phase 4 331-39-5, 501-16-6 1549111
Enoxolone Investigational Phase 4 471-53-4 18526330
19 Antioxidants Phase 4
20 Antiparasitic Agents Phase 4
21 Antiprotozoal Agents Phase 4
22 Antimalarials Phase 4
23 Antimitotic Agents Phase 4
24 Immunologic Factors Phase 4
25 Antibiotics, Antitubercular Phase 4
26 Antirheumatic Agents Phase 4
27 Immunosuppressive Agents Phase 4
28 Dermatologic Agents Phase 4
29 Antifungal Agents Phase 4
30 Protective Agents Phase 4
31 Cyclosporins Phase 4
32 Antilymphocyte Serum Phase 4
33 Calcineurin Inhibitors Phase 4
Tin Phase 4 7440-31-5
35 Tin Fluorides Phase 4
36 Fluorides Phase 4
37 Cariostatic Agents Phase 4
38 Pharmaceutical Solutions Phase 4
39 Antineoplastic Agents, Immunological Phase 4
40 Cytochrome P-450 CYP3A Inhibitors Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42 Calcium, Dietary Phase 4
43 Micronutrients Phase 4
44 Vitamins Phase 4
45 Trace Elements Phase 4
46 Vasoconstrictor Agents Phase 4
47 Nutrients Phase 4
48 Calciferol Phase 4
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
Dapsone Approved, Investigational Phase 3 80-08-0 2955

Interventional clinical trials:

(show top 50) (show all 342)
# Name Status NCT ID Phase Drugs
1 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
3 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
4 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
5 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
6 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
7 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
8 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
9 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
10 Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Completed NCT04089267 Phase 4 TPO
11 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
12 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
13 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Recruiting NCT03866798 Phase 4
14 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
15 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Recruiting NCT03784898 Phase 4
16 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
17 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
18 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
19 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
20 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
21 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
22 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
23 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
24 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
25 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Active, not recruiting NCT02760251 Phase 4 romiplostim
26 A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) Active, not recruiting NCT02255656 Phase 4 alemtuzumab GZ402673
27 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
28 Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia in Pediatrics Not yet recruiting NCT04102033 Phase 4 Eltrombopag
29 A Multicenter Randomized Open-label Clinical Trial of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP Not yet recruiting NCT04094805 Phase 4 Rocaltrol;Dexamethasone
30 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
32 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
33 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
34 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
35 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
36 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
37 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
38 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
39 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
40 Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00562835 Phase 2, Phase 3 Methylprednisolone
41 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
42 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076399 Phase 3 Fostamatinib disodium;Placebo
43 Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" Completed NCT00344149 Phase 3 Rituximab (Mabthera)
44 A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
45 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura Completed NCT02076412 Phase 3 Fostamatinib Disodium;Placebo
46 A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura Completed NCT00511147 Phase 3
47 A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP Completed NCT01520909 Phase 3 Eltrombopag;Placebo
48 Randomized Study of the Treatment of Primary Immune Thrombocytopenic Purpura (ITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone Versus High-dose Dexamethasone. Completed NCT00657410 Phase 3 dexamethasone;prednisone
49 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
50 Predictive Value of the Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura of Children and Adults. Completed NCT04070599 Phase 3

Search NIH Clinical Center for Thrombocytopenic Purpura, Autoimmune

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Vinblastine Sulfate

Cochrane evidence based reviews: purpura, thrombocytopenic, idiopathic

Genetic Tests for Thrombocytopenic Purpura, Autoimmune

Anatomical Context for Thrombocytopenic Purpura, Autoimmune

MalaCards organs/tissues related to Thrombocytopenic Purpura, Autoimmune:

Bone, Bone Marrow, T Cells, Spleen, B Cells, Thyroid, Liver

Publications for Thrombocytopenic Purpura, Autoimmune

Articles related to Thrombocytopenic Purpura, Autoimmune:

(show top 50) (show all 4413)
# Title Authors PMID Year
Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. 61 56
17827395 2008
Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. 61 56
15765787 2005
Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. 61 56
12472565 2002
Chronic idiopathic thrombocytopenic purpura. 61 56
7935660 1994
Idiopathic thrombocytopenic purpura in two elderly siblings. 61 56
4074042 1985
Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. 56
18654664 2008
Immune thrombocytopenic purpura. 56
11919310 2002
Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. 56
9742983 1998
Autoimmune thrombocytopenic purpura. 56
2413550 1985
Chronic immune thrombocytopenic purpura in monozygotic twins: genetic factors predisposing to ITP. 56
6890627 1982
Specificity of autoantibodies in autoimmune thrombocytopenia. 56
7032627 1982
Hereditary autoimmune thrombocytopenic purpura: an immunologic and genetic study. 56
7195175 1981
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 56
14850832 1951
Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults. 54 61
19525300 2010
[Expression of T-bet and GATA3 in children with acute idiopathic thrombocytopenic purpura]. 54 61
20113630 2010
High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. 54 61
19797730 2009
New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses. 54 61
19426124 2009
Interleukin 18 and interleukin 18 binding protein in patients with idiopathic thrombocytopenic purpura. 54 61
19077159 2009
Romiplostim. 54 61
19275274 2009
Single nucleotide polymorphism in DNMT3B promoter and the risk for idiopathic thrombocytopenic purpura in Chinese population. 54 61
18437543 2008
[Expression of co-stimulatory molecules and role of interleukin 18 in peripheral lymphocytes of patients with idiopathic thrombocytopenic purpura]. 54 61
17605869 2007
Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. 54 61
17241299 2007
Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. 54 61
16915226 2006
Novel heterozygous missense mutation in the second leucine rich repeat of GPIbalpha affects GPIb/IX/V expression and results in macrothrombocytopenia in a patient initially misdiagnosed with idiopathic thrombocytopenic purpura. 54 61
16519708 2006
[Curative effect of interleukin 11 on chronic idiopathic thrombocytopenic purpura]. 54 61
16584619 2006
Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura. 54 61
15870550 2005
Increased glycocalicin index and normal thrombopoietin levels in patients with idiopathic thrombocytopenic purpura with a decreased rate of platelet production. 54 61
15921398 2005
Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. 54 61
15629743 2004
Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. 54 61
15150079 2004
[A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura]. 54 61
15355668 2004
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. 54 61
14675413 2004
[Interleukin-18 and its related cytokines in plasma of patients with idiopathic thrombocytopenic purpura]. 54 61
14706156 2003
Soluble P-selectin, interleukin 6, and thrombopoietin levels in children with acute and chronic idiopathic thrombocytopenic purpura and their relationship with mega-dose methylprednisolone therapy: a pilot study. 54 61
12468916 2002
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. 54 61
12411315 2002
[Study on the relations between HLA-DRB1 alleles and idiopathic thrombocytopenic purpura in children]. 54 61
12170464 2002
Autoantibody to c-Mpl (thrombopoietin receptor) in systemic lupus erythematosus: relationship to thrombocytopenia with megakaryocytic hypoplasia. 54 61
12209520 2002
Plasma thrombopoietin levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura. 54 61
12150725 2002
The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. 54 61
11913997 2002
[The effects of thrombopoietin and interleukin-11 on bone marrow megakaryocytic progenitors in patients with chronic idiopathic thrombocytopenic purpura in vitro]. 54 61
12528552 2001
[The relativity study of thrombopoietin and chronic idiopathic thrombocytopenic purpura]. 54 61
11758228 2001
Colony-forming unit-megakaryocyte (CFR-meg) numbers and serum thrombopoietin concentrations in thrombocytopenic disorders: an inverse correlation in myelodysplastic syndromes. 54 61
11021750 2000
[Clinical study on interferon treatment of chronic idiopathic thrombocytopenic purpura]. 54 61
12545843 2000
[The sensitivity, specificity and predictive value of PAIgG, reticulated platelets, thrombopoietin levels, and platelet size for the differential diagnosis of thrombocytopenia]. 54 61
10624125 1999
Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias. 54 61
10525827 1999
Systemic causes of excessive uterine bleeding. 54 61
10513767 1999
Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. 54 61
9639498 1998
Increased thrombopoietin levels in idiopathic thrombocytopenic purpura patients with a poor response to steroid therapy. 54 61
9690802 1998
Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. 54 61
9657432 1998
Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. 54 61
9633881 1998
Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. 54 61
9369414 1997

Variations for Thrombocytopenic Purpura, Autoimmune

Copy number variations for Thrombocytopenic Purpura, Autoimmune from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21699 1 160500000 165500000 Copy number FCGR2C Idiopathic thrombocytopenic purpura
2 46119 10 77700000 82000000 Copy number BMPR1A Idiopathic thrombocytopenic purpura
3 121460 18 43500000 48200000 Copy number MADH4 Idiopathic thrombocytopenic purpura

Expression for Thrombocytopenic Purpura, Autoimmune

Search GEO for disease gene expression data for Thrombocytopenic Purpura, Autoimmune.

Pathways for Thrombocytopenic Purpura, Autoimmune

Pathways related to Thrombocytopenic Purpura, Autoimmune according to KEGG:

# Name Kegg Source Accession
1 Phagosome hsa04145
2 Osteoclast differentiation hsa04380
3 Fc gamma R-mediated phagocytosis hsa04666

Pathways related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
11.98 GP6 GP5 GP1BA F8
6 11.81 ITGB3 ITGA2B GP6 GP5 GP1BA
8 11.56 ITGB3 IL18 FCGR2C
9 11.5 SELP ITGB3 CD40LG
Show member pathways
11 11.38 ITGB3 ITGA2B GP6 GP5
12 11.37 SELP IL18 CD40LG
14 10.84 THPO ITGB3 ITGA2B IL18 IL11 CD40LG
15 10.72 GP6 GP5 GP1BA
16 10.55 GP5 GP1BA

GO Terms for Thrombocytopenic Purpura, Autoimmune

Cellular components related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.07 SELP S100A8 MPL LRBA ITGB3 ITGA2B
2 integral component of plasma membrane GO:0005887 9.87 SELP RHD ITGB3 GP6 GP5 GP1BA
3 cell surface GO:0009986 9.63 MPL ITGB3 ITGA2B GP6 GP1BA CD40LG
4 extracellular space GO:0005615 9.61 THPO SELP S100A8 IL18 IL11 IFNA2
5 platelet alpha granule membrane GO:0031092 8.8 SELP ITGB3 ITGA2B

Biological processes related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 SELP S100A8 IL18 IFNA2 CD40LG
2 cytokine-mediated signaling pathway GO:0019221 9.8 MPL IL18 IL11 IFNA2 GATA3
3 integrin-mediated signaling pathway GO:0007229 9.69 ITGB3 ITGA2B CD40LG
4 platelet degranulation GO:0002576 9.67 SELP ITGB3 ITGA2B F8
5 B cell differentiation GO:0030183 9.65 IL11 IFNA2 CD40LG
6 hemostasis GO:0007599 9.56 GP6 GP5 GP1BA F8
7 blood coagulation, intrinsic pathway GO:0007597 9.5 GP5 GP1BA F8
8 positive regulation of leukocyte migration GO:0002687 9.49 SELP ITGA2B
9 platelet aggregation GO:0070527 9.46 MPL ITGB3 ITGA2B GP1BA
10 thrombopoietin-mediated signaling pathway GO:0038163 9.43 THPO MPL
11 platelet activation GO:0030168 9.43 ITGB3 GP6 GP5 GP1BA F8 CD40LG
12 blood coagulation GO:0007596 9.17 ITGB3 IFNA2 GP6 GP5 GP1BA GATA3

Molecular functions related to Thrombocytopenic Purpura, Autoimmune according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 SELP S100A8 MPL LRBA ITGB3 ITGA2B
2 cytokine activity GO:0005125 9.02 THPO IL18 IL11 IFNA2 CD40LG
3 fibrinogen binding GO:0070051 8.96 ITGB3 ITGA2B

Sources for Thrombocytopenic Purpura, Autoimmune

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....